Parexel (PRXL) is one of those companies that fall into the category of being large and fairly profitable, but not exactly in the public's eye. The one possible incident that may possibly ring a bell is a 2006 trial by the now-defunct German pharmaceutical company TeGenero, which Parexel ran. As a brief summary, TeGenero's now infamous drug TGN1412 was tested on humans for the first time and led to multiple organ failure in six patients, launching a firestorm in the process, as one would imagine. Granted, this is far into Parexel's past and has little bearing on the massive potential the company has in the coming months.
Parexel belongs to the family of contract research organizations (...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: